British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...
The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...
The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...
President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.
Pfizer (PFE) shares slipped on Wednesday after The Wall Street Journal reported that U.S. authorities are investigating ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results